BioSpace News Archive

eLab assay is geared for on-site testing applications such as nursing homes, schools, travel venues, and businesses

In a release issued under the same headline earlier by Myovant Sciences, please note that in the first paragraph of the release, the presentation time should be 2:50 p.m. Eastern Time, not 2:50 p.m.

180 Life Sciences Corp., a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference.

First of Its Kind Program Features 550+ Executive Women Leaders for Board Seats and the C-Suite

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in January.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the following upcoming investor conferences in January:

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. ET on Thursday, January 14, 2021.

RespireRx Pharmaceuticals Inc., has, on January 4, 2021, filed with the Secretary of State of the State of Delaware a Sixth Certificate of Amendment to its Second Restated Certificate of Incorporation.

Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has closed its previously announced public offering of 11,600,000 shares of common stock,